BOARD

MARIA KEFALAS & PAT CARR

Founders

Maria Kefalas and Patrick Carr, Founders. Ms. Kefalas is a professor in the Department of Sociology at Saint Joseph's University and Mr. Carr is associate professor and director of the Criminal Justice Program at Rutgers University-New Brunswick. Both earned doctorates in Sociology from the University of Chicago. 

TIM BLIAMPTIS, MBA

Advisory Board Member

Mr. Bliamptis is a Managing Director of Weathergage Capital, which he founded in 2006. He began his investment career in the Treasurer’s Office at the Massachusetts Institute of Technology, where he focused on the endowment’s venture capital investments. He holds degrees in Electrical Engineering from MIT and an MBA from The Wharton School, University of Pennsylvania.

RACHEL KAISER, MD AND MPH

Advisory Board Member

Dr. Kaiser is a rheumatologist in private practice in the Washington D.C. area. Prior to focusing full-time on clinical practice, she was on the faculty of the Division of Rheumatology at the University of California, San Francisco (UCSF) where her research focused on genetic risk factors of blood clots in lupus patients.

ANDREW SHENKER, MD, PhD

Advisory Board Member

Dr. Shenker is a pediatric physician-scientist with expertise in cell signaling, disease pathophysiology and genotype-phenotype relationships, gene therapy, and the clinical development of novel treatments for rare metabolic and neurological diseases, including metachromatic leukodystrophy and other lysosomal storage disorders.He has over 20 years of experience in academic, biotech and pharmaceutical industry settings, most recently as Vice President, GlaxoSmithKline Rare Diseases. He currently works as an independent consultant.

Amy Waldman, MD

Scientific Advisor

Dr. Waldman is Attending Physician, Assistant Professor of Neurology, Perelman School of Medicine at the University of Pennsylvania and serves as Medical Director of the Leukodystrophy Center of Excellence.


 

JILL CAIRNS MILNE, PH.D

Advisory Board Member

Dr. Milne is the President and CEO of Catabasis, a Cambridge, MA based biotech.  Prior to founding Catabasis, Dr. Milne worked as the head of discovery biology at Sirtris Pharmaceuticals and a served as the worldwide head of the Drug Pfinder Program and head of the Enzyme Target Group at the Pfizer Discovery Technology Center. She holds a Ph.D. from Harvard University and a B.A. in biological chemistry from Wellesley College.

ADELINE VANDERNER,MD

Scientific Advisor

Dr. Vanderver is a Jacob A. Kamens Endowed Chair in Neurological Disorders and Translational NeuroTherapeutics at The Children’s Hospital of Philadelphia. Dr. Vanderver is an international leader in the study of leukodystrophies.

Every dollar matters to help families, improve care, and accelerate research that will cure leukodystrophies and related neurological diseases in the fast-approaching future.

 

The CJF is a registered 501c(3) with tax id no. 90-1005140.

TCJF Certificate of Registration.JPG

View 501(c)3

Registration Certificate

TCJF 990 Form.JPG

View TCJF

990 Tax Form

TCJF 2018 Report.JPG

2018-2019 Annual Report

Cals Cupcake 5K

No one draws a salary for our efforts on behalf of children with leukodystrophy. We rely on the work of volunteers, neighbors, and friends.

 
Cal's Cupcakes | Nord Rare Impact Award

Maria Kefalas and The Calliope Joy Foundation 
are proud to announce that we are recognized for a

2018 Rare Impact Award from NORD. 

https://rarediseases.org/rare-impact-awards/

TCJF is a member of the National Organization for Rare Disorders
WE WELCOME YOUR DONATION

​​Call us:

610-664-1588

Mailing Address: 

The Calliope Joy Foundation

PO Box 2866

Bala Cynwyd, PA 19004

$0
$1,000,000

501(c)(3) Status:

View here

Amazon Smile:

Visit here

NORD Member:

Learn more here

© 2019 by Cal's Cupcakes | The Calliope Joy Foundation. Proudly created by CAZ Media Design

The Calliope Joy Foundation - Cals Cupca
0